- Trial phase
- Approved
- Time to market
- Already approved and commercially available since October 2019.
- Why 4/10
- VUMERITY is already FDA-approved and commercially marketed with no pending PDUFA date, pivotal readout, or regulatory decision scheduled in the next 12 months. As an approved drug without a binary catalyst, the impact score defaults to 4 per the rubric.
VUMERITY has no upcoming FDA catalyst; the next material event for Biogen is the litifilimab Phase 3 SLE readout expected in December 2026. For VUMERITY specifically, watch quarterly sales trends and any generic patent challenges as the 2033 loss-of-exclusivity date approaches.
Price Chart
Executive Summary
VUMERITY (diroximel fumarate) is an FDA-approved oral therapy for relapsing forms of multiple sclerosis, developed by Biogen (BIIB) in partnership with Alkermes. Approved in 2019 as a next-generation follow-up to Biogen's Tecfidera, it offers improved gastrointestinal tolerability. In Q3 2026, VUMERITY generated $192M in in-market sales, down 11% year-over-year, reflecting ongoing pressure on Biogen's MS franchise from generic Tecfidera competition and payer dynamics. A June 2026 real-world study showed fewer MS relapses with VUMERITY versus Tecfidera, providing a potential differentiation point. Patent protection extends to 2033, with no generic diroximel fumarate currently on the market. VUMERITY is a modest contributor to Biogen's Growth Portfolio, which is increasingly driven by newer products like SPINRAZA, LEQEMBI, and SYFOVRE.
How It Works
VUMERITY is an oral capsule taken twice daily for relapsing forms of multiple sclerosis. Once swallowed, the body rapidly converts it into monomethyl fumarate, the same active molecule. While the exact mechanism is not fully understood, it is thought to reduce inflammation and activates antioxidant response genes, which helps reduce MS relapses and delays disability progression. It is a next-generation version of Biogen's older drug Tecfidera, designed to cause fewer gastrointestinal side effects.
Trial Status
VUMERITY was approved by the FDA in October 2019 via the 505(b)(2) pathway based on pharmacokinetic bridging studies showing bioequivalence to Tecfidera. A Phase 3 EVOLVE-MS-2 study demonstrated improved gastrointestinal tolerability versus Tecfidera. An ongoing observational study (NCT05767736) is evaluating long-term safety in over 10,000 patients. A June 2026 real-world study found significantly lower MS relapse rates with VUMERITY versus Tecfidera.
The Two-Sided Case
Upcoming Catalysts
- No upcoming FDA catalyst specific to VUMERITY. The drug is already approved and marketed. Watch quarterly sales trends for continued erosion or stabilization.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOGEN INC. 8-K BIIB ·Originating report